For hematological malignancies CRISPR-Cas9 target genes include TRAC, B2M, CD7, CD28, CD19, CD20 and CD22 (NCT03190278, NCT03166878, NCT03398967, NCT03690011), depending on the cancer characteristics. The gene discussed is CD19; the disease is hematologic disorder.